CSI parent company to self-produce indoxacarb


June 23, 2022



ADAMA, parent company of Pasadena, Texas-based Control Solutions Inc. (CSI), has begun the in-house production of indoxacarb, a key insecticide active ingredient. This is part of ADAMA’s new proprietary synthesis process, providing a building block for its differentiated formulations.

Producing this complex molecule with an innovative, cost-effective process is expected to improve ADAMA’s supply chain performance while opening access to a global market of approximately $200 million in indoxacarb sales as of 2021.

ADAMA has launched a number of mixtures and formulations based on indoxacarb, which deliver significant pest control in a variety of affected crop and countries as well as for pest professionals.

“With its vast global market potential, we identified indoxacarb as a key building block for ADAMA’s future differentiated product pipeline,” said Elad Shabtai, EVP Global Operations at ADAMA. “This new in-house production capability of indoxacarb is expected to improve the Company’s control over the availability, quality and cost of this important active ingredient. Moreover, our indoxacarb formulations deliver powerful solutions, thus combining our AI cost position with superior product features on the formulation side”

ADAMA is targeting more than 15 countries with its self-produced indoxacarb, including leading markets in the USA, Brazil and India. It is a key active ingredient for various insecticides, including ADAMA’s products Plethora (India, Brazil), Plemax (Australia, South Africa) and Doxem (U.S.).

In addition to the potential sales of indoxacarb, ADAMA expects to expand the production and sales of its proprietary active ingredient, novaluron, due to increased demand, given that these two active ingredients are paired together in formulations to provide a highly effective solution against chewing pests in their early stages of development.


About the Author

Ellen Wagner is a former digital editor for PMP magazine.

Leave A Comment

Comments are closed.